Form 4 Filing for Arrowhead Pharmaceuticals, Inc.

On December 19, 2025, Adeoye Y Olukotun, a director at Arrowhead Pharmaceuticals, Inc. (ARWR), sold a total of 10,000 shares of common stock. These sales were executed under a Rule 10b5-1 trading plan. The transactions included 3,090 shares at a weighted average price of $66.70, 6,083 shares at a weighted average price of $68.04, and 827 shares at a weighted average price of $68.48. The sales occurred at prices ranging from $66.52 to $68.56. Following these transactions, the reporting person holds 33,600 shares. The filing also notes that the reported shares include those underlying Restricted Stock Units that are still subject to vesting conditions.